|Exchange:||NASDAQ national market|
|Stock:||Cubist Pharmaceuticals, Inc.|
|Cubist Pharmaceuticals, Inc. was incorporated as a Delaware corporation in 1992. It went public in 1996. The Company is engaged in the research, development & commercialization of novel therapies to treat unmet medical needs in acute care environment. It provides CUBICIN, a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; and ENTEREG, an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. The company also co-promotes DIFICID for the treatment of clostridium difficile-associated diarrhea. In addition, its development products include Ceftolozane/tazobactam that is in Phase III clinical trials to treat complicated urinary tract infections and complicated intra-abdominal infections. Further, the company is developing ceftolozane/tazobactam for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Additionally, it develops Surotomycin, an oral lipopeptide, which is in Phase III clinical trials to treat CDAD; Bevenopran, an oral, peripherally-acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in patients with chronic non-cancer pain; and CB-625 that is in Phase I clinical studies to treat acute pain and various inflammatory conditions. In addition, its pre-clinical programs include therapies to treat various bacterial infections and agents to treat acute pain.|
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.